Opendata, web and dolomites

UCRxF

A novel ulcerative colitis treatment - A phase III ready feasibility study

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 UCRxF project word cloud

Explore the words cloud of the UCRxF project. It provides you a very rough idea of what is the project "UCRxF" about.

partnering    index    reinvested    license    immunomodulatory    royalties    business    generate    preparations    asset    portfolio    reported    upfront    sales    manufacturing    diseases    chronic    planning    debilitating    additional    biological    stockholm    medical    inflammation    science    uc    cobitolimod    colon    continue    larger    party    moderate    demonstrated    2018    ab    compounds    purpose    action    severe    offers    primary    patients    safety    commercial    clinical    iib    strategy    caused    efficacy    broad    park    colitis    treat    finance    treatment    company    innovative    feasibility    ready    initiation    licensing    revenues    line    institutet    international    dims    drug    milestone    q4    companies    attractiveness    tested    karolinska    approved    platform    dna    fast    sweden    acute    ulcerative    unmet    preparation    toxicology    profile    efficient    prior    medication    cure    immunological    sequences    deal    pharmaceutical    active    disease    pharmaceuticals    drugs    payments    mechanism   

Project "UCRxF" data sheet

The following table provides information about the project.

Coordinator
INDEX PHARMACEUTICALS AB 

Organization address
address: TOMTEBODAVAGEN 23A
city: STOCKHOLM
postcode: 171 77
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://www.indexpharma.com/en/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INDEX PHARMACEUTICALS AB SE (STOCKHOLM) coordinator 50˙000.00

Map

 Project objective

InDex Pharmaceuticals AB is a pharmaceutical development company based at the Karolinska Institutet Science Park in Stockholm, Sweden. The company´s primary asset is cobitolimod, which is in late phase clinical development as a new medication to treat moderate to severe active ulcerative colitis (UC); a chronic, debilitating disease with a high unmet medical need. UC is caused by chronic inflammation of the colon, and there is no cure.

Cobitolimod offers a novel and unique mechanism of action for the treatment of UC, and has demonstrated a higher efficacy and better safety profile in clinical studies than what has been reported for currently approved biological drugs. Cobitolimod is part of the broad InDex portfolio of DNA-based ImmunoModulatory Sequences (referred to as DIMS), which have the potential for treatment of various immunological diseases. Cobitolimod is currently being tested in a phase IIb clinical study with top line results expected in Q4 2018.

InDex’s business strategy is to out-license cobitolimod to a larger international pharmaceutical company prior to the initiation of clinical phase III development. This will generate revenues for InDex from upfront and milestone payments as well as royalties from third party sales, which can then be reinvested in the company to finance development of new compounds from the DIMS technology platform.

For clinical phase III, additional manufacturing and toxicology work as well as commercial preparations are essential. The planning and preparation of this work is the purpose of this feasibility study, which is a crucial part of the cobitolimod phase III ready programme, increasing the attractiveness of the asset in partnering discussions with pharmaceutical companies looking for innovative new products. A licensing deal will ensure that the development of this promising, innovative drug will continue in a fast and efficient way to reach patients with this debilitating disease.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "UCRXF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "UCRXF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More